Age |
42.5 years (15–78 years) |
Sex |
Males: 156, females: 94 |
Total WBC |
15,400/cu mm (166–480,000) |
Platelet count |
32,000/cu mm (4000–486,000) |
Hb |
8.2 mg% (3–18) |
Blast% |
68% (21–100) |
LDH |
850 U/l (206–9963) |
Creatinine |
1 mg% (0.54–4.7) |
WHO classification (n = 250) |
AML with recurrent genetic abnormalities |
101 (40.4%) |
AML with MDS-related features |
44 (17.6%) |
AML not otherwise specified |
105 (42.0%) |
Cytogenetic risk group (n = 248) |
Favorable |
27 (10.9%) |
Intermediate |
144 (58.1%) |
Adverse |
77 (31.0%) |
Normal karyotype |
112 (45.1%) |
Molecular markers |
NPM1 mutation (n = 245) |
79 (32.3%) |
FLT3-ITD (n = 245) |
43 (17.55%) |
FLT3-TKD (n = 244) |
10 (4.3%) |
t (8:21) (RUNX1-RUNX1T1) (n = 244) |
20 (8.9%) |
inv 16 (CBFB-MYH11) (n = 244) |
11 (4.7%) |